Skip to main content

Vaccinex, Inc.

corporate_fare Company Profile

Vaccinex, Inc.

VCNX·OTC·Life Sciences·CIK 0001205922

Vaccinex, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted biologic therapies for serious diseases with unmet medical needs, such as neurodegenerative diseases, cancer, and autoimmune disorders. The company identifies itself as a leader in semaphorin 4D (SEMA4D) biology and states it is the only company targeting SEMA4D for potential treatment of these conditions. SEMA4D is an extracellular signaling molecule that regulates immune and inflammatory cell activity. Vaccinex has utilized its SEMA4D antibody platform and knowledge of SEMA4D biology to develop its lead product candidate, pepinemab, an antibody. The company is primarily focused on developing pepinemab for Alzheimer's disease, and as resources permit, also for head and neck cancer and pancreatic cancer. Third-party investigators have also studied pepinemab in clinical trials for breast cancer and in "window of opportunity" studies for other indications, including melanoma. Vaccinex has developed multiple proprietary platform technologies and product candidates. Its SEMA4D antibody platform includes pepinemab, which is in clinical development for Alzheimer's disease, head and neck cancer, pancreatic cancer, and breast cancer, through company efforts or investigator-sponsored trials. An additional product candidate, VX5, is in an earlier stage of development and was selected using the ActivMAb platform.

Vaccinex, Inc. (OTC:VCNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for VCNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-08, rated 8/10.

Recent high-impact activity:

  • Vaccinex to Present Promising Biomarker Data, Unveil Enlarged Phase 2B Alzheimer's Trial Plans

Financial Snapshot

Fiscal year ended December 31, 2024
Revenue
$601K
Net Income
-$18.63M
Diluted EPS
-$8.88
Op. Cash Flow
-$16.19M
Free Cash Flow
-$16.21M
Operating Income
-$18.73M
Cash & Equivalents
$1.11M
Total Debt
$25K
Debt / Equity
-0.01×
Net Margin
-31.00×
Shares Outstanding
2.68M sh
Source: 10-K · filed 2025-04-15 · accession 0000950170-25-054318

Short Interest & Short Volume

3.18 days to cover

FINRA reported short interest of 2,106 shares in VCNX as of the October 30, 2026 settlement, a 23.4% decrease from the prior period — about 3.2 days to cover at its recent average daily volume. On November 18, 2026, 80.6% of VCNX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,106 shares as of October 30, 2026
Change vs prior period▼ 23.4%
Days to cover3.18 at avg daily volume of 662
Daily short volume (FINRA facilities)80.6% of 5,620 shares on November 18, 2026
4-day average short volume83.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.9743 +8.26% today
52-week range · as of 2026-07-08 $0.2521 – $1.5
Market cap
$2.61M
Volume
1.1K (1.0× avg)
3-mo avg 1K
Live data · 2026-11-22 07:39 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VCNX - Latest Insights

VCNX
Jul 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9743 info
Change: -$0.1457 (-13%) info
Market Cap: $2.608M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets